Original Articles
Peng Wei, Bo Liu, Ruifeng Wang, Yinglei Gao, Lanlan Li, Yuchi Ma, Zhiwei Qian, Yuelei Chen, Maosheng Cheng, Meiyu Geng, Jingkang Shen, Dongmei Zhao, Jing Ai, Bing Xiong. Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study[J]. Acta Pharmaceutica Sinica B, 2019, 9(2): 351-368

Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study
Peng Weia,b, Bo Liuc, Ruifeng Wanga,b, Yinglei Gaoc, Lanlan Lic, Yuchi Mab, Zhiwei Qianb, Yuelei Chenb, Maosheng Chenga, Meiyu Gengc, Jingkang Shenb, Dongmei Zhaoa, Jing Aic, Bing Xiongb
a Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China;
b Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;
c Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Genomic alterations are commonly found in the signaling pathways of fibroblast growth factor receptors (FGFRs). Although there is no selective FGFR inhibitors in market, several promising inhibitors have been investigated in clinical trials, and showed encouraging efficacies in patients. By designing a hybrid between the FGFR-selectivity-enhancing motif dimethoxybenzene group and our previously identified novel scaffold, we discovered a new series of potent FGFR inhibitors, with the best one showing sub-nanomolar enzymatic activity. After several round of optimization and with the solved crystal structure, detailed structure-activity relationship was elaborated. Together with in vitro metabolic stability tests and in vivo pharmacokinetic profiling, a representative compound (35) was selected and tested in xenograft mouse model, and the result demonstrated that inhibitor 35 was effective against tumors with FGFR genetic alterations, exhibiting potential for further development.
Key words:    Fibroblast growth factor    Tyrosine kinase receptor    Structure-based    Crystallography    Selectivity    Hybrid    5-Hydrosulfonyl-5H-pyrrolo[2,3-b]pyrazine    Inhibitor   
Received: 2018-08-15     Revised: 2018-11-09
DOI: 10.1016/j.apsb.2018.12.008
Funds: We are grateful for financial support from the National Natural Science Foundation of China (Grants No.81661148046 and 81773762,China) and the "Personalized Medicines-Molecular Signature-based Drug Discovery and Development",Strategic Priority Research Program of the Chinese Academy of Sciences (Grants No.XDA12020317,China),the program for Innovative Research Team of the Ministry of Education (China),and the program for Liaoning Innovative Research Team at Shenyang Pharmaceutical University (China).
Corresponding author: Dongmei Zhao, Jing Ai, Bing Xiong     Email:Zhaodm@syphu.edu.cn;jai@simma.c.cn;bxiong@simm.ac.cn
Author description:
PDF(KB) Free
Peng Wei
Bo Liu
Ruifeng Wang
Yinglei Gao
Lanlan Li
Yuchi Ma
Zhiwei Qian
Yuelei Chen
Maosheng Cheng
Meiyu Geng
Jingkang Shen
Dongmei Zhao
Jing Ai
Bing Xiong

1. The Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The cancer genome Atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
2. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018;173:400-416.e11.
3. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 2018;173:321-37.e10.
4. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 2015;36:422-39.
5. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies:progress, challenges and future directions. Mol Cancer 2018;17:48.
6. Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B 2017;7:27-37.
7. Harrison PT, Huang PH. Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays Biochem 2018;62:583-93.
8. Lategahn J, Keul M, Rauh D. Lessons to be learned:the molecular basis of kinase-targeted therapies and drug resistance in non-small cell lung cancer. Angew Chem Int Ed Engl 2018;57:2307-13.
9. Guan X. Cancer metastases:challenges and opportunities. Acta Pharm Sin B 2015;5:402-18.
10. Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, et al. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol 2017;13:994-1001.
11. Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 2017;17:318-32.
12. Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res 2015;21:2684-94.
13. Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev 2016;46:51-62.
14. Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci 2016;37:1081-96.
15. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer:analysis of 4,853 tumors by nextgeneration sequencing. Clin Cancer Res 2016;22:259-67.
16. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, et al. Fibroblast growth factor family aberrations in cancers:clinical and molecular characteristics. Cell Cycle 2015;14:2121-8.
17. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the FGFR pathway:opportunities for targeted therapies in solid tumors. Ann Oncol 2014;25:552-63.
18. Hierro C, Rodon J, Tabernero J. Fibroblast growth factor (FGF) receptor/FGF inhibitors:novel targets and strategies for optimization of response of solid tumors. Semin Oncol 2015;42:801-19.
19. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted panFGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012;11:690-9.
20. Cheng W, Wang M, Tian X, Zhang X. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. Eur J Med Chem 2017;126:476-90.
21. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547:an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045-56.
22. Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer 2017;117:1592-9.
23. Jiang A, Liu Q, Wang R, Wei P, Dai Y, Wang X, et al. Structure-based discovery of a series of 5H-pyrrolo[2,3-b]pyrazine FGFR kinase inhibitors. Molecules 2018;23:698.
24. Tucker JA, Klein T, Breed J, Breeze AL, Overman R, Phillips C, et al. Structural insights into FGFR kinase isoform selectivity:diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure 2014;22:1764-74.
25. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000:the integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 2006;D62:859-66.
26. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Echols N, Headd JJ, et al. The Phenix software for automated determination of macromolecular structures. Methods 2011;55:94-106.
27. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 2011;D67:355-67.
28. Emsley P, Cowtan K. Coot:model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;D60:2126-32.
Similar articles:
1.Wennan Zhao, Yuling Qiu, Dexin Kong.Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy[J]. Acta Pharmaceutica Sinica B, 2017,7(1): 27-37
2.Dhulfiqar Ali Abed, Melanie Goldstein, Haifa Albanyan, Huijuan Jin, Longqin Hu.Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents[J]. Acta Pharmaceutica Sinica B, 2015,5(4): 285-299
3.Nagaraju Anreddy, Atish Patel, Kamlesh Sodani, Rishil J.Kathawala, Eugenie P.Chen, John N.D.Wurpel, Zhe-Sheng Chen.PD173074,a selective FGFR inhibitor,reverses MRP7(ABCC10)-mediated MDR[J]. Acta Pharmaceutica Sinica B, 2014,4(3): 202-207